Razlika između verzija stranice "Xeroderma pigmentosum"
| [pregledana izmjena] | [pregledana izmjena] |
Uklonjeni sadržaj Dodani sadržaj
No edit summary oznaka: uređivanje izvornog kôda (2017) |
Rescuing 1 sources and submitting 0 for archiving.) #IABot (v2.0.8.5 |
||
Red 1:
{{italic title}}
{{infokutija bolest
|ime = ''Xeroderma pigmentosum''<br>(DeSanctis-Cacchioneov sindrom)<br>(XP1/XP2/XP3/XP4/XP5/XP6/XP7)<ref name="myriad1">{{Cite web|title=https://myriadwomenshealth.com/2014/05/hello-world/|url=https://myriadwomenshealth.com/2014/05/hello-world/|access-date=2020-07-05|website=Myriad Women's Health|language=en-US}}{{Mrtav link}}</ref><br>
(''Xeroderma pigmentosum'' I/II/III/IV/V/VI/VII)<br>(Komplementna grupa ''xeroderma pigmentosum'' A/B/C/D/E/F/G) <br>(''Xeroderma pigmentosum'' grupa A/B/C/D/E/F/G)
| slika = Xeroderma pigmentosum 02.jpg
Red 94:
Ne postoji lijek za poremećaj; svo liječenje je simptomsko ili preventivno. Simptomi se mogu izbjeći ili kontrolirati potpunim izbjegavanjem izlaganja sunčevoj svjetlosti, bilo boravkom u zatvorenom prostoru ili nošenjem zaštitne odjeće i korištenjem [[krema za sunčanje]] na otvorenom.<ref>{{cite book|last1=Nussbaum|first1=Robert|last2=McInnes|first2=Roderick|last3=Willard|first3=Huntington | name-list-style = vanc |title=Genetics in Medicine|publisher=Elsevier|isbn=978-14377-0696-3|date=2016-01-01}}</ref> [[Keratoza]] također može biti tretirana korištenjem [[Krioterapija|krioterapije]] or [[fluorouracil|fluorouracila]].<ref name="Halpern_2008">{{cite journal | vauthors = Halpern J, Hopping B, Brostoff JM | title = Photosensitivity, corneal scarring and developmental delay: Xeroderma Pigmentosum in a tropical country | journal = Cases Journal | volume = 1 | issue = 1 | pages = 254 | date = October 2008 | pmid = 18937855 | pmc = 2577106 | doi = 10.1186/1757-1626-1-254 }}</ref> U težim slučajevima XP-a, čak i male količine UV-zraka, naprimjer, iz pokrivenih prozora ili fluorescentnih sijalica, mogu biti vrlo opasne i izazvati simptome.<ref>{{Cite web|last1=DelhiSeptember 24|first1=india today digital New|last2=September 24|first2=2014UPDATED|last3=Ist|first3=2014 09:56|title=Xeroderma pigmentosum|url=https://www.indiatoday.in/lifestyle/health/story/story/xeroderma-pigmentosum/1/391127-300570-2014-09-24|access-date=2020-07-05|website=India Today|language=en}}</ref>
Dana 10. septembra 2020., Clinuvel Pharmaceuticals je objavio da istražuje upotrebu svog vodećeg lijeka pod imenom [[Scenesse]], koji je odobrila FDA za potencijalno liječenje i povećanje bezbolnog izlaganja svjetlu za pacijente sa ''xeroderma pigmentosum''.<ref>{{Cite web|title=SCENESSE® (afamelanotide 16mg) – Welcome to CLINUVEL|url=https://www.clinuvel.com/pharmaceutical/scenesse/scenesse|access-date=2020-09-24|archive-date=20. 10. 2020|archive-url=https://web.archive.org/web/20201020100319/https://www.clinuvel.com/pharmaceutical/scenesse/scenesse|url-status=dead}}</ref><ref>{{Cite web|last=Commissioner|first=Office of the|date=2020-03-24|title=FDA approves first treatment to increase pain-free light exposure in patients with a rare disorder|url=https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-increase-pain-free-light-exposure-patients-rare-disorder|access-date=2020-09-24|website=FDA|language=en}}</ref><ref>{{Cite web|title=Scenesse (afamelanotide) for adults with a history of phototoxic reactions from EPP|url=https://scenesse.com/|access-date=2020-09-24|website=SCENESSE® (Afamelanotide)|language=en-US}}</ref>
== Prognoza ==
| |||